Table 2.
IHC features of PsA and Abneg RA cohorts based on the achievement of MDA and DAS remission after 6 months follow-up
| PsA cohort | ||||||
| Naive (N = 12) | p | MTX-IR (N = 22) | p 1 | |||
| MDA (N = 6) | No MDA (N = 6) | MDA (N = 9) | No MDA (N = 13) | |||
| Follicular synovitis, n (%) | 3 (50.0) | 3 (50.0) | 1.00 | 3 (33.3) | 7 (53.8) | 0.34 |
| CD68 (L) (mean ± SD) | 1.58 ± 0.80 | 2.42 ± 0.73 | 0.09 | 1.86 ± 0.90 | 2.0 ± 1.07 | 0.77 |
| CD68 (SL) (mean ± SD) | 1.25 ± 1.08 | 2.16 ± 0.61 | 0.13 | 1.77 ± 0.93 | 2.0 ± 1.07 | 0.54 |
| CD21 (mean ± SD) | 0.58 ± 0.92 | 0.92 ± 1.02 | 0.59 | 0.96 ± 0.80 | 0.33 ± 0.43 | 0.06 |
| CD20 (mean ± SD) | 0.83 ± 0.82 | 1.17 ± 0.93 | 0.56 | 1.19 ± 0.83 | 1.06 ± 0.40 | 0.64 |
| CD3 (mean ± SD) | 0.91 ± 0.33 | 1.99 ± 0.84 | 0.02 | 1.65 ± 0.77 | 2.11 ± 0.96 | 0.29 |
| CD117 (mean ± SD) | 1.16 ± 0.82 | 1.42 ± 0.49 | 0.62 | 1.12 ± 0.62 | 1.39 ± 0.61 | 0.32 |
| CD138 (mean ± SD) | 0.67 ± 0.75 | 1.25 ± 0.88 | 0.25 | 0.58 ± 0.64 | 0.61 ± 0.60 | 0.84 |
| CD31+ vessels (mean ± SD) | 32.50 ± 13.41 | 40.75 ± 6.84 | 0.39 | 22.81 ± 11.31 | 25.21 ± 13.06 | 0.58 |
| Abneg RA cohort | ||||||
| Naive (N = 27) | p 2 | MTX-IR (N = 28) | p 3 | |||
| REM (N = 11) | No REM (N = 16) | REM (N = 11) | No REM (N = 17) | |||
| Follicular synovitis, n (%) | 6 (46.2) | 6 (42.6) | 0.86 | 3 (27.3) | 7 (41.2) | 0.45 |
| CD68 (L) (mean ± SD) | 1.86 ± 0.82 | 2.23 ± 0.68 | 0.27 | 2.10 ± 0.51 | 1.97 ± 0.83 | 0.82 |
| CD68 (SL) (mean ± SD) | 0.92 ± 0.58 | 2.13 ± 0.55 | < 0.001 | 1.35 ± 0.78 | 1.46 ± 0.76 | 0.66 |
| CD21 (mean ± SD) | 0.39 ± 0.74 | 0.65 ± 1.08 | 0.79 | 0.54 ± 0.79 | 0.77 ± 1.13 | 0.78 |
| CD20 (mean ± SD) | 1.64 ± 1.02 | 1.23 ± 0.78 | 0.26 | 1.46 ± 0.99 | 1.44 ± 0.83 | 0.85 |
| CD3 (mean ± SD) | 1.57 ± 0.95 | 1.57 ± 0.83 | 0.98 | 1.59 ± 0.89 | 1.47 ± 0.87 | 0.49 |
| CD117 (mean ± SD) | 0.57 ± 0.43 | 0.62 ± 0.46 | 0.79 | 0.77 ± 0.56 | 0.56 ± 0.43 | 0.28 |
| CD138 (mean ± SD) | 1.54 ± 0.99 | 1.77 ± 1.05 | 0.55 | 1.36 ± 1.07 | 1.62 ± 1.28 | 0.47 |
| CD31+ vessels (mean ± SD) | 35.64 ± 7.69 | 34.64 ± 6.89 | 0.54 | 22.35 ± 5.28 | 21.88 ± 5.78 | 0.52 |
Data presented in italics have p < 0.05
PsA psoriatic arthritis, Ab autoantibody, RA rheumatoid arthritis, MDA Minimal Disease Activity, REM remission, DAS Disease Activity Score, p naive PsA reaching MDA vs naive PsA not achieving MDA, p1 MTX-IR PsA reaching MDA vs MTX-IR PsA not achieving MDA, p2 naive ABneg RA reaching DAS remission vs naive ABneg RA not achieving DAS remission, p3 MTX-IR ABneg RA reaching DAS remission vs MTX-IR ABneg RA not achieving DAS remission, MTX-IR methotrexate inadequately responder